SEC Filing Summary: PerkinElmer, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PerkinElmer, Inc. on September 10, 2021. The filing details the entry into a material definitive agreement involving a public offering of senior notes to fund a portion of the cash consideration for the acquisition of BioLegend, Inc.
Key Financial Metrics and Debt Issuance
The Company issued a total of $2.3 billion in aggregate principal amount of senior notes across four tranches:
- 2023 Notes: $500 million at 0.550% interest, maturing September 15, 2023.
- 2024 Notes: $800 million at 0.850% interest, maturing September 15, 2024.
- 2028 Notes: $500 million at 1.900% interest, maturing September 15, 2028.
- 2031 Notes: $500 million at 2.250% interest, maturing September 15, 2031.
Proceeds and Liquidity: The Company expects net proceeds of approximately $2.28 billion after deducting underwriting discounts and offering expenses. These proceeds, combined with cash on hand and up to $500 million from a delayed draw term loan facility, will fund the BioLegend Acquisition. Following the issuance, the remaining commitment on the 364-day senior unsecured bridge term loan facility was reduced to $514.0 million.
Material Changes and Use of Proceeds
The primary material change is the increase in long-term debt obligations to finance the BioLegend Acquisition. The notes are general unsecured obligations, effectively subordinated to secured indebtedness and subsidiary liabilities but ranking equal with other unsecured debt. Interest payments are semi-annual, commencing March 15, 2022.
Redemption Terms, Risks, and Contingencies
Redemption Provisions:
- The 2023 and 2024 Notes cannot be redeemed prior to September 15, 2022.
- The 2028 and 2031 Notes have specific "Par Call Dates" (July 15, 2028, and June 15, 2031, respectively) after which they may be redeemed at 100% of principal plus accrued interest.
- Early redemption prior to Par Call Dates is subject to a make-whole provision based on Treasury rates plus 15 basis points.
Contingencies and Risks:
- Mandatory Redemption: If the BioLegend Acquisition is not consummated by January 31, 2022, or the merger agreement is terminated prior to that date, the Company must redeem all notes at 101% of principal plus accrued interest.
- Change of Control: Upon a Change of Control Repurchase Event, the Company must offer to repurchase the notes at 101% of principal plus accrued interest.
- Covenants: The Indenture restricts the creation of liens on Principal Property and sale-leaseback transactions involving such property.
Investor Verification Checklist
- Verify the closing status and timeline of the BioLegend, Inc. acquisition to assess the risk of mandatory redemption.
- Review the full text of the Seventh Supplemental Indenture (Exhibit 4.2) for detailed covenant restrictions.
- Confirm the utilization of the $500 million delayed draw term loan facility and the remaining $514 million bridge loan commitment.
- Monitor the Company's liquidity position to ensure ability to service the new debt and fund the remainder of the acquisition.